Cognitive function in a randomized trial of evolocumab

Robert P. Giugliano; Marc S. Sabatine; Brian R. Ott; Gary Wittert

doi:10.1056/NEJMc1712102

Cognitive function in a randomized trial of evolocumab

Robert P. Giugliano, Marc S. Sabatine, Brian R. Ott, Gary Wittert

Nutrition, Diabetes And Gut Health

Research output: Contribution to journal › Article › peer-review

110 Citations (Scopus)

Abstract

Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.

Original language	English
Journal	New England Journal of Medicine
Volume	377
Issue number	20
DOIs	https://doi.org/10.1056/NEJMc1712102
Publication status	Published or Issued - 16 Nov 2017

ASJC Scopus subject areas

General Medicine

Access to Document

10.1056/NEJMc1712102

https://www.nejm.org/doi/full/10.1056/NEJMoa1701131

Cite this

@article{d49943393af145f1a7ce514418c60ec3,

title = "Cognitive function in a randomized trial of evolocumab",

abstract = "Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.",

author = "Giugliano, {Robert P.} and Sabatine, {Marc S.} and Ott, {Brian R.} and Gary Wittert",

year = "2017",

month = nov,

day = "16",

doi = "10.1056/NEJMc1712102",

language = "English",

volume = "377",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "20",

}

TY - JOUR

T1 - Cognitive function in a randomized trial of evolocumab

AU - Giugliano, Robert P.

AU - Sabatine, Marc S.

AU - Ott, Brian R.

AU - Wittert, Gary

PY - 2017/11/16

Y1 - 2017/11/16

N2 - Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.

AB - Findings from clinical trials of proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors have led to concern that these drugs or the low levels of low-density lipoprotein (LDL) cholesterol that result from their use are associated with cognitive deficits.

UR - http://www.scopus.com/inward/record.url?scp=85033786488&partnerID=8YFLogxK

U2 - 10.1056/NEJMc1712102

DO - 10.1056/NEJMc1712102

M3 - Article

C2 - 29141161

AN - SCOPUS:85033786488

SN - 0028-4793

VL - 377

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 20

ER -

Cognitive function in a randomized trial of evolocumab

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this